← All tickers

Is IONS Worth Buying in 2026?

Ionis Pharmaceuticals, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-08-23

Here’s whether Ionis Pharmaceuticals, Inc. Common Stock (IONS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Positives: strong 1-year return of +38.2%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-4.97% over 10 days); 3-month momentum negative (-20.9%). Currently 31.1% off its 52-week high. Score: -4/7.

Ready to act on this? 📈 Trade on Webull

IONS is trading below its 200-day MA ($73.99) — a key warning sign the longer-term trend is under pressure. An RSI of 67.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +38.2% compares to +20.5% for SPY (beat the market by 17.7%). The current 31.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $13,818 today
vs. S&P 500 (SPY) — same period beat market by 17.7%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 200-day MA ($73.99)
✗Above 50-day MA ($64.02)
✓RSI(14) neutral zone (30–70) — currently 67.0
✓Positive return (+38.2%)
!Within 10% of period high (−31.1%)
Period Range $59.74
$41.71 $86.74
RSI (14) 67.0
0 · OversoldOverbought · 100

Key Metrics

Price$59.74
Period Return+38.2%
Period High$86.74
Period Low$41.71
Drawdown−31.1%
MA-50$64.02
MA-200$73.99
RSI (14)67.0
Avg Volume (30d)3.0M
vs. SPYbeat by 17.7%
Return Rank#301 of 999

Trade IONS

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers